Show simple item record

Safety Analyses of the Phase 3 VISION Trial of [ <SUP>177 </SUP>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

dc.contributor.authorChi, KN
dc.contributor.authorArmstrong, AJ
dc.contributor.authorKrause, BJ
dc.contributor.authorHerrmann, K
dc.contributor.authorRahbar, K
dc.contributor.authorde Bono, JS
dc.contributor.authorAdra, N
dc.contributor.authorGarje, R
dc.contributor.authorMichalski, JM
dc.contributor.authorKempel, MM
dc.contributor.authorFizazi, K
dc.contributor.authorMorris, MJ
dc.contributor.authorSartor, O
dc.contributor.authorBrackman, M
dc.contributor.authorDesilvio, M
dc.contributor.authorWilke, C
dc.contributor.authorHolder, G
dc.contributor.authorTagawa, ST
dc.date.accessioned2024-06-25T12:17:54Z
dc.date.available2024-06-25T12:17:54Z
dc.date.issued2024-04-01
dc.identifier.citationEuropean Urology, 2024, 85 (4), pp. 382 - 391en_US
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6271
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2023.12.004
dc.identifier.doi10.1016/j.eururo.2023.12.004
dc.format.extent382 - 391
dc.languageEnglish
dc.language.isoengen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofEuropean Urology
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectUrology & Nephrology
dc.subjectMetastatic castration-resistant
dc.subjectprostate cancer
dc.subjectRadioligand therapy
dc.subjectLu-177-PSMA-617
dc.subjectTreatment-emergent adverse
dc.subjectevents
dc.subjectTreatment exposure
dc.subjectRADIOLIGAND THERAPY
dc.subjectOPEN-LABEL
dc.subjectMULTICENTER
dc.subjectEFFICACY
dc.titleSafety Analyses of the Phase 3 VISION Trial of [ <SUP>177 </SUP>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Canceren_US
dc.typeJournal Article
dcterms.dateAccepted2023-12-11
dc.date.updated2024-06-25T12:16:52Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.eururo.2023.12.004en_US
rioxxterms.licenseref.startdate2024-04-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.issue4
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.eururo.2023.12.004
pubs.volume85
icr.researchteamPrCa Targeted Therapyen_US
dc.contributor.icrauthorDe Bono, Johann
icr.provenanceDeposited by Mr Arek Surman on 2024-06-25. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0302283823032979-main.pdf


Files in this item

Thumbnail
Name:
1-s2.0-S0302283823032979-main.pdf
Size:
1.386Mb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/